期刊
NEURODEGENERATIVE DISEASE MANAGEMENT
卷 2, 期 4, 页码 421-435出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.12.34
关键词
-
资金
- Huntington's Disease Society of America
- Cure Huntington's Disease Initiative Foundation, Inc.
- National Institute of Neurological Disorders and Stroke [R01 NS 37564]
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that typically begins in middle adulthood. The neurodegenerative process that underlies HD, however, likely begins many years before clinical diagnosis. Since genetic testing can identify individuals that will develop HD during this preclinical period, clinical trials aiming to slow disease progression will likely focus on this phase of the illness in an effort to delay disease onset. How to best measure the efficacy of potential disease-modifying therapies in preclinical HD remains a complex challenge. This article will review the clinical and imaging measures that have been assessed as potential markers of disease progression in preclinical and early symptomatic HD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据